TY - JOUR

T1 - Protocol for a prospective, longitudinal study of cognitive impairment in young patients with cancer

T2 - A multidisciplinary neuroscience approach (MyBrain)

AU - Nordhjem, Barbara Johanne Thomas

AU - Tjørnlund, Morten

AU - Thomsen, Birthe Lykke

AU - Hjerming, Maiken

AU - Kjær, Troels Wesenberg

AU - Pappot, Helle

AU - Hjalgrim, Lisa Lyngsie

N1 - Funding Information: This work has been supported by the Danish Childhood Cancer Foundation (grant number 2020-6785; grant number 2021-7442) the Novo Nordisk Foundation (grant number NNF21OC0072440), the Danish Cancer Society (grant number R260-A15221), and Helsefonden (grant number 18-B-0276). Publisher Copyright: © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2023

Y1 - 2023

N2 - Introduction The aim of this research is to investigate young cancer patients' cognitive functioning and the underlying neurobiological mechanisms when cognitive functions are impaired. The MyBrain protocol is a multidisciplinary study that investigates cancer-related cognitive impairment in children, adolescents and young adults, combining neuropsychology, cognitive neuroscience and cellular neuroscience. The study is exploratory with a wide focus on trajectories of cognitive functions from diagnosis to the end of treatment and into survivorship. Methods and analysis Prospective longitudinal study including patients diagnosed with non-brain cancers at age 7-29 years. Each patient is paired with a control matched on age and social circle. Primary objective Evaluation of neurocognitive function over time. Secondary objectives Evaluation of self-perceived quality of life and fatigue, P300 in an electroencephalography (EEG) oddball paradigm, power spectrum in resting state EEG, serum and cerebrospinal fluid levels of biomarkers of neuronal damage, neuroplasticity, proinflammatory and anti-inflammatory markers and their association with cognitive function. Ethics and dissemination The study is approved by the Regional Ethics Committee for the Capital Region of Denmark (no. H-21028495), and the Danish Data Protection Agency (no. P-2021-473). Results are expected to guide future interventions to prevent brain damage and support patients with cognitive difficulties. Trial registration number The article is registered at clinicaltrials.gov NCT05840575 (https://clinicaltrials.gov/ct2/show/NCT05840575)

AB - Introduction The aim of this research is to investigate young cancer patients' cognitive functioning and the underlying neurobiological mechanisms when cognitive functions are impaired. The MyBrain protocol is a multidisciplinary study that investigates cancer-related cognitive impairment in children, adolescents and young adults, combining neuropsychology, cognitive neuroscience and cellular neuroscience. The study is exploratory with a wide focus on trajectories of cognitive functions from diagnosis to the end of treatment and into survivorship. Methods and analysis Prospective longitudinal study including patients diagnosed with non-brain cancers at age 7-29 years. Each patient is paired with a control matched on age and social circle. Primary objective Evaluation of neurocognitive function over time. Secondary objectives Evaluation of self-perceived quality of life and fatigue, P300 in an electroencephalography (EEG) oddball paradigm, power spectrum in resting state EEG, serum and cerebrospinal fluid levels of biomarkers of neuronal damage, neuroplasticity, proinflammatory and anti-inflammatory markers and their association with cognitive function. Ethics and dissemination The study is approved by the Regional Ethics Committee for the Capital Region of Denmark (no. H-21028495), and the Danish Data Protection Agency (no. P-2021-473). Results are expected to guide future interventions to prevent brain damage and support patients with cognitive difficulties. Trial registration number The article is registered at clinicaltrials.gov NCT05840575 (https://clinicaltrials.gov/ct2/show/NCT05840575)

KW - CHEMOTHERAPY

KW - HAEMATOLOGY

KW - MENTAL HEALTH

KW - Neurobiology

KW - ONCOLOGY

KW - PAEDIATRICS

U2 - 10.1136/bmjopen-2022-070534

DO - 10.1136/bmjopen-2022-070534

M3 - Journal article

C2 - 37202143

AN - SCOPUS:85159769202

VL - 13

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 5

M1 - e070534

ER -